Pfizer's arthritis drug shows efficacy in late-stage trial

06/20/2010 | Reuters

Patients with rheumatoid arthritis demonstrated significant reduction in knee pain and improvement in physical function after receiving one of three doses of Pfizer's injectable biotech drug tanezumab during a late-stage trial. The medicine targets nerve growth factor, a protein associated with pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI